Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-3: Copanlisib + Rituximab vs Placebo + Rituximab in Relapsed iNHL
CTR20160337Phase 3Terminated
- Sponsor
- Bayer
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of copanlisib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL), Waldenström macroglobulinemia (WM), sponsored by Bayer. Started Nov 2016; status: terminated.
02
Drugs
copanlisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on CTR20160337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160337.